23andMe Holding Co. (ME)

Market Cap	281.83M
Revenue (ttm)	247.99M
Net Income (ttm)	-521.97M
Shares Out	482.92M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,988,208
Open	0.581
Previous Close	0.597
Day's Range	0.574 - 0.610
52-Week Range	0.350 - 2.200
Beta	1.24
Analysts	Buy
Price Target	3.24 (+452.15%)
Earnings Date	May 23, 2024

About ME

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliat...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 769
• Stock Exchange: NASDAQ
• Ticker Symbol: ME

Financial Performance

In 2022, ME's revenue was $299.49 million, an increase of 10.15% compared to the previous year's $271.89 million. Losses were -$311.66 million, 43.3% more than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for ME stock is "Buy." The 12-month stock price forecast is $3.24, which is an increase of 452.15% from the latest price.

Price Target

$3.24

(452.15% upside)

Analyst Consensus: Buy